244 results about "Chronic sinusitis" patented technology

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues).

Chronic sinusitis is treated by the application of cold plasma or plasma-activated species to the infected mucosal surfaces through use of an endoscope having a steerable end which may be projected into the sinus cavities through the nasal cavity. The cold plasma is generated at either the distal end of the endoscope with a power source by application of a power, or at the distal end by gas and electrical connections extending through the endoscope. The cold plasma or plasma-activated species act to destroy bacterial cells but not eukaryotic cells.

The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and / or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

The present invention relates to a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent sinusitis comprising budesonide at a therapeutically effective dose of less than 16 mcg and a pharmaceutically acceptable liquid carrier.

Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.

Chronic sinusitis is treated by the application of cold plasma or plasma-activated species to the infected mucosal surfaces through use of an endoscope having a steerable end which may be projected into the sinus cavities through the nasal cavity. The cold plasma is generated at either the distal end of the endoscope with a power source by application of a power, or at the distal end by gas and electrical connections extending through the endoscope. The cold plasma or plasma-activated species act to destroy bacterial cells but not eukaryotic cells.

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

An eyeglass system comprising conventional eyeglasses and a cold weather protective shield in either one combined unit or in a removable form. The present invention is particularly directed towards people who suffer from chronic sinusitis. The shield component may be integrally attached to the eye glass frame or be releasably attached to a standard-style eyeglass frame (either of which can be fitted with standard size and shape prescription lenses), to provide protection against cold weather. The preferred embodiment of the removable assembly includes a one-piece member having side retaining members with the member serving as the frame, side retaining members, and a top retaining member.

In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

The present invention relates to a Chinese patent medicine for effectively curing the diseases of chronic simple rhinitis, hypertrophic rhinitis, allergic rhinitis, atrophic rhinitis and nasal polyp, etc. with obvious therapeutic effect. Said Chinese patent medicine is made up by using 22 Chinese medicinal materials of xanthium fruit, magnolia flower, dahurian angelica root, Chinese lovage root, ligusticum root, white peony root, ginseng and others through a certain preparation process. Said invention can be made into pill preparation, and its cure rate is 91.6%.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

This invention relates to a kind of medicinal preparation which has the therapeutic function of chronic nasosinusitis. It is characterized in that the medicament is made up of some high grade raw materials including Lonicera japonica Thunb, Dendranthema morifolium, Magnolia liliflora, Fructus xanthii, Herba Menthae, Radix Angelicae Dahuricae, Manchurian Wildginger, Herba Taraxaci, Foliumisatidis, Houttuynia cordata, Ligusticum wallichii, Radix Angelica, Scutellaria, Semen Coicis Coix lachrymal, Gypsum Fibrosuum, Radix Glycyrrhizae and so on. All the raw materials are mixed according to the definite ratio of weight. The medicament is decocted and taken by oral administration. A dosage is taken in a day and fifteen days as a course of treatment. It is characterized in its high curative ratio, obvious therapeutic effectiveness, symptoms removed rapidly, non-toxic side effectiveness, lower cost of therapy, non-relapse and capable of eliminating pains radically. In all, the medicament can be used in therapy of chronic nasosinusitis effectively. According to clinical trial, the effective rate, the effectual rate and the cure rate of the medicament is up to 96.7%, 87.9% and 63.7%, respectively.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma.The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

The invention discloses a Chinese medicinal composition for treating children chronic sinusitis. The oral taken medicine comprises the following active ingredients in part by weight: 10 to 20 parts of Chinese angelica, 10 to 20 parts of xanthium sibiricum, 10 to 20 parts of nutgrass galingale rhizome, 10 to 20 parts of weeping forsythia, 10 to 20 parts of wax gourd seed, 10 to 20 parts of Szechuan lovage rhizome, 10 to 20 parts of platycodon root, 10 to 20 parts of sargent gloryvine, 10 to 20 parts of heartleaf houttuynia herb, 10 to 20 parts of astragalus, 10 to 20 parts of biond magnolia flower, 10 to 20 parts of angelica dahurica, 10 to 20 parts of baical skullcap root, 10 to 20 parts of Mongolian dandelion herb, 10 to 20 parts of honeysuckle and 10 to 20 parts of fineleaf schizonepetaherb; the external application medicine comprises the following active ingredients in part by weight: 10 to 20 parts of honeysuckle, 10 to 20 parts of nutgrass galingale rhizome, 10 to 20 parts of borneol, 10 to 20 parts of mint, 10 to 20 parts of manchurian wildginger, 10 to 20 parts of chrysanthemum, 10 to 20 parts of safflower, 10 to 20 parts of bletilla striata, 10 to 20 parts of divaricate saposhnikovia root and 10 to 20 parts of frankincense. The Chinese medicinal composition makes a nasal part lesion subjected to benign simulation so as to clear the meridians, dispel blood block, accelerate blood smoothness and achieve an effect of strengthening body resistance and eliminating evil, and has a better clinical effect through combined treatment of oral administration and external application.

The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans.

The invention discloses a pharmaceutical composition for clearing away heat and toxic material, dispelling wind and eliminating swelling and relieving sore throat to be sensible. The pharmaceutical composition is mainly prepared by extracting the following effective components of a dozen of medical materials including figwort root, cocklebur fruit, cassia twig, magnolia flower, dahurian angelica root, frosythia fruit, honeysuckle flower, lilyturf root, dandehon herb, liquorice, balloonflower root, cape jasmine, scutellaria root, red peony root, coix seed, rehmannia root, and the like. The specific active components of the pharmaceutical composition have the effects of clearing away heat and toxic material, dispelling wind and eliminating swelling and relieving sore throat to be sensible and are used for various symptoms such as acute and chronic nasal sinusitis, rhinitis, faucitis, and the like caused by the wind heat.

The invention relates to a traditional medicine composite for treating chronic rhinitis, wherein compared with present technique, it is fried via 18-22 deals of gingelly oil into oil, and it comprises 4.0-4.5 deals of xanthostrumarin, 0.8-1.2 deals of magnolia flower, and 1.8-2.2 deals of dahurian angelica root. The invention has wide application and low cost.

The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.

The invention relates to a pharmaceutical composition with effects of awakening consciousness, clearing away heat and toxic material, eliminating dampness and discharging pus and a preparation method thereof. The pharmaceutical composition is prepared by the following bulk drugs according to proportioning by weight: 80-320 parts of indian bread, 80-320 parts of frosythia fruit, 80-320 parts of pilose asiabell root, 80-320 parts of belamcanda rhizome, 80-320 parts of biond magnolia flower, 80-320 parts of grassleaved sweetflag rhizome, 80-320 parts of white atractylodes rhizome, 80-320 parts of tangerine peel, 50-200 parts of Chinese yam, 50-200 parts of cocklebur fruit, 50-200 parts of red peony root, 80-320 parts of dahurian angelica root, 50-200 parts of trichosanthes root, 50-200 parts of balloonflower root, 50-200 parts of liquorice and 50-200 parts of chuanxiong rhizome and is processed into clinically accepted tablets, capsules or granules through extracting, refining and other processes. The invention has the effects of awakening consciousness, clearing away heat and toxic material and eliminating dampness and discharging pus, is generally used for nasosinusitis syndrome or stagnated heat of lung channel of nose therapy and can be also used for throat swelling and pain; and the invention is usually used for acute nasosinusitis, acute episode of chronic nasosinusitis and acute faucitis nowadays.

A Chinese medicine in the form of dripping pill, dispersing tablet, or micropill for treating chronic rhinitis and nasosinusitis is prepared from xanthium fruit, honeysuckle flower, wild chrysanthemum flower, magnolia flower and madder. Its preparing process and quality control method are also disclosed.

This invention provides an external use medincet for treating chronic rhinitis and nasosinusitis. It is prepared by using the following Chinese medical ingredients according to their weight ratio: American ginseng 15-3, peony root bark 12-5,Chinese angelica root 12-5,towelgourd vascular bundles 10-5,balloon-flower 10-5,puncturevine caltrap fruit 10-5, coptis rhizome0-5,membranous milkvetch root 10-5,ginseng 10-5,sevenlobed yam rhizome 8-5,pumice8-5,fructus forsythiae 8-5,Dahurian angelica root 5-1,biond magnolia flower-bud 5-1,skebia stem 5-1,siberian cocklebur fruit 5-1,cassiabarktree bark 3-1,manchurian whildginger herb 3-1.In the aspect of the medical application, it is convenient and easy to use with light side effects, no irritatations to the skin and obvious curative effects. According to statistics that the total effective ratio for treating chronic rhinitis, chronic nasosinusitis is above 95%.

A process for preparing Chinese medicine "Biyanling capsule" for treating chronic nasosinusitis, rhinitis, nasal congestion, etc includes such steps as extracting from xanthium fruit by alcohol, decocting dregs, concentrating, drying, extracting volatile oil of magnolia flower and asarum herb, pulverizing 4 Chinese-medicinal materials including scutellaria root, mixing, granulating, adding menthol and additive, mixing all together, and loading in capsules. Its advantage is high curative effect and safety.